News Snapshot:
February 09, 2021 08:28 ET | Source: Research and Markets Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Recombinant Human Thrombopoietin Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. In recent years, the incidence of thrombopenia in China keeps increasing. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30%...
